Personalized Gene Therapy Solutions Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PERSONALIZED GENE THERAPY SOLUTIONS MARKET BY TECHNOLOGY

1. 5.1. Introduction

2. 5.2. CRISPR-Cas9

3. 5.3. Base Editing

4. 5.4. Prime Editing

5. 5.5. TALENs

6. 5.6. Zinc Finger Nucleases (ZFNs)

7. 5.7. Viral Vector-Based Gene Therapy

8. 5.8. Non-Viral Gene Delivery Technologies

6. PERSONALIZED GENE THERAPY SOLUTIONS MARKET BY APPLICATION

1. 6.1. Introduction

2. 6.2. Oncology

3. 6.3. Rare Genetic Disorders

4. 6.4. Cardiovascular Diseases

5. 6.5. Neurological Disorders

6. 6.6. Metabolic Disorders

7. 6.7. Infectious Diseases

7. PERSONALIZED GENE THERAPY SOLUTIONS MARKET BY END-USER

1. 7.1. Introduction

2. 7.2. Pharmaceutical & Biotechnology Companies

3. 7.3. Academic & Research Institutes

4. 7.4. Hospitals & Specialty Clinics

5. 7.5. Contract Research Organizations (CROs)

8. PERSONALIZED GENE THERAPY SOLUTIONS MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. Novartis AG

2. 10.2. F. Hoffmann-La Roche Ltd.

3. 10.3. Pfizer Inc.

4. 10.4. Gilead Sciences Inc.

5. 10.5. Sarepta Therapeutics

6. 10.6. CRISPR Therapeutics

7. 10.7. Beam Therapeutics

8. 10.8. Intellia Therapeutics

9. 10.9. bluebird bio

10. 10.10. Sangamo Therapeutics

11. 10.11. Adverum Biotechnologies

12. 10.12. Oxford Biomedica

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations